These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33128909)

  • 41. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.
    Liu Z; He W; Gao J; Luo J; Huang X; Gao C
    Oncotarget; 2015 Apr; 6(10):8019-35. PubMed ID: 25749522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.
    Barberis C; Pribish J; Tserlin E; Gross A; Czekaj M; Barragué M; Erdman P; Maniar S; Jiang J; Fire L; Patel V; Hebert A; Levit M; Wang A; Sun F; Huang SA
    Bioorg Med Chem Lett; 2019 Feb; 29(3):491-495. PubMed ID: 30553737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
    Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
    Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of 1,6-dihydropyrazolo[4,3-c]carbazoles and 3,6-dihydropyrazolo[3,4-c]carbazoles as new Pim kinase inhibitors.
    Suchaud V; Gavara L; Saugues E; Nauton L; Théry V; Anizon F; Moreau P
    Bioorg Med Chem; 2013 Jul; 21(14):4102-11. PubMed ID: 23735828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
    Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions.
    Mohareb RM; Abouzied AS; Abbas NS
    Anticancer Agents Med Chem; 2019; 19(12):1438-1453. PubMed ID: 31038076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
    Oyallon B; Brachet-Botineau M; Logé C; Bonnet P; Souab M; Robert T; Ruchaud S; Bach S; Berthelot P; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Eur J Med Chem; 2018 Jun; 154():101-109. PubMed ID: 29778892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterocyclization of 2-(2-phenylhydrazono)cyclohexane-1,3-dione to Synthesis Thiophene, Pyrazole and 1,2,4-triazine Derivatives with Anti-Tumor and Tyrosine Kinase Inhibitions.
    Mohareb RM; Alwan ES
    Anticancer Agents Med Chem; 2020; 20(10):1209-1220. PubMed ID: 32156245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterocyclization of Thiophenes Derived from Estrone Followed by Cytotoxic, HTRF Kinase and Pim-1 Kinase Evaluations.
    Mahmoud MAA; Mohareb RM; Al-Sharif MA
    Anticancer Agents Med Chem; 2018; 18(12):1711-1728. PubMed ID: 29732981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis of Tetrahydrobenzo[
    Mohareb RM; Wardakhan WW; Abbas NS
    Anticancer Agents Med Chem; 2019; 19(14):1737-1753. PubMed ID: 30947678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
    Pastor J; Oyarzabal J; Saluste G; Alvarez RM; Rivero V; Ramos F; Cendón E; Blanco-Aparicio C; Ajenjo N; Cebriá A; Albarrán MI; Cebrián D; Corrionero A; Fominaya J; Montoya G; Mazzorana M
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1591-7. PubMed ID: 22266039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
    Nafie MS; Amer AM; Mohamed AK; Tantawy ES
    Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
    Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
    Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
    Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
    Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
    Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
    Abouzid KAM; Al-Ansary GH; El-Naggar AM
    Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.